A dispute within the FDA on whether to put new lung-cancer warnings on ARBs taken by millions of people is unlikely to have any significant effect on the manufacturers stocks.
Cramer has been looking at long-term losers to see if any show potential. He’s found something.
CFO Simon Dingemans says GlaxoSmithKline's re-engineered approach to R&D is bearing fruit.
An antibiotic-resistant strain of gonorrhea has some saying that its effects could match those of AIDS.
The FDA has lowered the age limit for Plan B One-Step emergency contraceptive to 15. The pill will be available without a prescription and stocked on store shelves.
Big pharma is abandoning antibiotic research at a time when fears over superbugs are growing at an alarming rate, leaving smaller firms to fill the breach.
Most robotic surgery takes place without a hitch, but a growing number of complaints and lawsuits allege complications and even deaths from Intuitive Surgical's da Vinci device.
If the critics of robotic surgery are right—that safety is an issue—how is that it was performed on 450,000 people last year? The answer may lie in one word: Marketing.
The number of complications from robot-assisted surgery using Intuitive Surgical's da Vinci robot are underreported, allege critics of the procedure, fanning the controversy around the company's pioneering product.
Intuitive Surgical's da Vinci robot was once hailed as a revolution in the operating room, but as more reports of complications have come to light, the da Vinci debate is heating up.
San Diego is at ease with sandy beaches, and biotechnology.
Johnson & Johnson just won approval for a new diabetes drug, and the stock is at an all-time high today. Anthony Butler, Barclays, offers insight.
Most big chain restaurants now put nutrition information on their menus. How accurate are these numbers? NBC News takes a closer look.
In recent years, as the surgical robot's popularity has grown, so have questions and concerns about its safety, training and the aggressiveness of its marketing.
"It's going to look more like the rounding error in GDP," says one economist. "I think there is a lot more noise than light being shed on the sequester."
U.S. regulators dealt a major blow to Novo Nordisk's hopes for its new long-acting insulin Tresiba by demanding the Danish drugmaker conduct additional clinical tests to assess potential heart risks.
NPS Pharmaceuticals CEO Dr. Francois Nader discusses the approval of its short bowel syndrome drug Gattex, and what's next for the company.
NPS Pharmaceuticals president & CEO Dr. Francois Nader, discusses strategies his company uses to finding value for shareholders, and appealing to the FDA.
One options trader is making a big bet on Monster Beverage amid the stock's decline, with CNBC contributor Mike Khouw of CRT Capital Group LLC.
Monster Beverage responds to the five deaths reported to the FDA citing the energy drink, reports CNBC's Eamon Javers.